Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant

Trial ID or NCT#



not recruiting iconNOT RECRUITING


This phase 2 trial studies the side effects and how well midostaurin works in treating older patients with acute myeloid leukemia with change in genetic material post-hematopoietic cell transplantation. Midostaruin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving midostaruin post-transplant may improve patient outcomes.

Official Title

An Open-Label Extension Study of Post-Transplant Maintenance Midostaurin (PKC412) in Elderly Patients (Age ≥ 60 Years) With FLT3-ITD/TKD Mutated AML Who Previously Received Midostaurin and Decitabine as Part of Study HEMAML0022 / CPKC412AUS27T

Eligibility Criteria

Ages Eligible for Study: Older than 60 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


David Iberri
David Iberri
Clinical Assistant Professor, Medicine - Hematology

Contact us to find out if this trial is right for you.


Jack Taw